Related Experiment Video
Updated: Jul 24, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with
Stefan Schreiber1, David T Rubin2, Siew C Ng3
1Department of Internal Medicine, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
Journal of Crohn'S & Colitis
|July 4, 2023
Summary
Tofacitinib for ulcerative colitis patients showed major adverse cardiovascular events were more common in those with prior cardiovascular disease or higher baseline risk. Individual risk assessment is crucial for managing cardiovascular health in these patients.
Area of Science:
- Cardiovascular Medicine
- Gastroenterology
- Pharmacology
Background:
- Patients with inflammatory bowel disease, including ulcerative colitis (UC), face an elevated risk of atherosclerotic cardiovascular disease (ASCVD).
- Tofacitinib, an oral Janus kinase inhibitor, is used to treat UC.
- Assessing cardiovascular (CV) risk in UC patients treated with tofacitinib is important.
Purpose of the Study:
- To analyze major adverse cardiovascular events (MACE) within the UC OCTAVE program.
- To stratify MACE rates based on patients' baseline cardiovascular risk profiles.
Main Methods:
- MACE rates were analyzed according to baseline CV risk: prior ASCVD or 10-year ASCVD risk categories (low, borderline, intermediate, high).
- Data were collected from patients in the UC OCTAVE program treated with tofacitinib.
Main Results:
- Of 1157 patients, 4% had prior ASCVD and 83% had low-borderline baseline 10-year ASCVD risk.
- Eight patients (0.7%) experienced MACE; one had prior ASCVD.
- MACE incidence rates were higher in patients with prior ASCVD and those with higher baseline 10-year ASCVD risk.
Conclusions:
- Most UC patients in the OCTAVE program had low baseline CV risk.
- MACE occurred more frequently in patients with a history of ASCVD and higher baseline CV risk.
- Individualized CV risk assessment is recommended for UC patients treated with tofacitinib.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
01:29Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
563
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
563
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
223
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
223
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156